The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Hello Heart | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $145.53MM | Series D | 5/2/2022 | $70MM | $666.71MM | $7.41 | Stripes, IVP, Resolute Ventures, BlueRun Ventures | |||||
| Iambic Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $336.52MM | Series B-4 | 4/1/2026 | $27.77MM | $664.28MM | $3.26 | Undisclosed Investors | |||||
| Candid Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $370MM | Series B | 9/9/2024 | $190.26MM | $660.51MM | $1.20 | Venrock, Fairmount Partners, TCG Crossover Management, venBio Partners, Foresite Capital, Third Rock Ventures, Fidelity, Samsara BioCapital, Qiming Venture Partners, OrbiMed, Boxer Capital, Redmile Group, Vida Ventures, Two River, Franklin Templeton, LifeSci Venture Partners, Mirae Asset Capital Life Science, Polaris Partners, Soleus Capital | |||||
| Calyxo | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $155.79MM | Series F | 3/26/2026 | $40.1MM | $658.2MM | $8.82 | Undisclosed Investors | |||||
| TraceLink | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $278.43MM | Series D | 8/21/2018 | $60MM | $657MM | $16.01 | Georgian Partners, Vulcan Capital, Willett Advisors, FirstMark Capital, Volition Capital, F-Prime Capital, Goldman Sachs | |||||
| Paige | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $247.3MM | Series C-1 | 3/2/2023 | $19.5MM | $656.14MM | $25.74 | Undisclosed Investors | |||||
| Qualified Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $155.06MM | Series A | 3/25/2026 | $122.31MM | $649.53MM | $32.65 | New Enterprise Associates, Transformation Capital, GreatPoint Ventures, Cathay Innovation, Menlo Ventures, Anthropic, SignalFire, Frist Cressey Ventures, Flare Capital Partners, Healthier Capital, Town Hall Ventures, Intermountain Ventures | |||||
| Quartet Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $279.11MM | Series B | 12/10/2021 | $60MM | $646.74MM | $11.26 | Independence, GV, Oak HC/FT | |||||
| Rakuten Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $874.92MM | Series F-3 | 1/7/2026 | $3.6MM | $636.9MM | $1.03 | Taiwania Capital, Axil Capital Group, Daiwa Securities, Mitsui Sumitomo Insurance Company, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, OEP Group, SBI Group, Rakuten, Mickey Mikitani | |||||
| Abpro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $69.53MM | Series F | 3/30/2022 | $2MM | $628.78MM | $18.00 | Undisclosed Investors | |||||
| Apprentice | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $189.97MM | Series C | 3/20/2023 | $151.97MM | $622.45MM | $12.48 | Alkeon Capital Management, Silverton Partners, Insight Partners, Pacific Western Bank, Colorcon Ventures, ICONIQ Growth | |||||
| OncoC4 | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $131.23MM | Series B | 10/2/2025 | $50MM | $619.93MM | $4.66 | Greater Bay Area Homeland Investments, HM Capital, 3E Bioventures Capital, Kaitai Capital | |||||
| DNAnexus | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.14B | Series I | 3/8/2022 | $200MM | $616.31MM | $0.61 | Blackstone Growth, Northpond Ventures, GV, Perceptive Advisors, Innovatus Capital Partners, Foresite Capital | |||||
| Avenzo Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $433.08MM | Series B | 9/5/2025 | $47.23MM | $615.68MM | $2.22 | Undisclosed Investors | |||||
| Rightway | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $349.52MM | Series D | 3/25/2024 | $108.75MM | $615.59MM | $20.78 | Undisclosed Investors | |||||
| CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $510.76MM | Series F | 8/2/2023 | $105.02MM | $615.24MM | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | |||||
| Loyal | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $236.56MM | Series C | 2/11/2026 | $95.46MM | $614.38MM | $12.26 | Age 1, Baillie Gifford | |||||
| Carrot | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $146.82MM | Series D | 8/18/2022 | $50MM | $611.49MM | $9.74 | Undisclosed Investors | |||||
| Artera | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $113.44MM | Series D | 12/3/2025 | $20MM | $608.01MM | $9.93 | Lead Edge Capital, Jackson Square Ventures, Health Velocity Capital, Heritage Medical Systems, Summation Health Ventures | |||||
| Found Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $132.31MM | Series BB | 12/16/2021 | $100MM | $601.15MM | $1.83 | WestCap, IVP, The Chernin Group, G9 Ventures, Able Partners, GV, Atomic, Define Ventures, Fidji Simo, Julia Cheek | |||||
| Notable | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $126.5MM | Series B | 11/3/2021 | $100MM | $600.67MM | $3.49 | ICONIQ Growth, Greylock Partners, F-Prime Capital, Oak HC/FT | |||||
| Vividion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $267.82MM | Series C | 2/24/2021 | $135MM | $600.09MM | $2.10 | Logos Capital, Boxer Capital, SoftBank, Avoro Capital Advisors, BlackRock, RA Capital Management, T. Rowe Price Associates, Surveyor Capital, Woodline Partners, Acuta Capital, Driehaus Capital Management, ARCH Venture Partners, BVF Partners, Casdin Capital, Mubadala Capital, Nextech Invest, Versant Ventures | |||||
| Latent | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $94.02MM | Series A | 3/18/2026 | $80MM | $600MM | $0.33 | Spark Capital, Transformation Capital, Conviction, McKesson Ventures, General Catalyst, Y Combinator | |||||
| RayzeBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $795.51MM | Series D | 9/13/2022 | $159.75MM | $599.64MM | $2.50 | Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.